FDA Advisory Panel Unanimously Backs Moderna’s mRNA Influenza Vaccine

The U.S. Food and Drug Administration’s (FDA) independent advisory committee voted unanimously on June 19, 2026, to support approval of Moderna’s seasonal mRNA influenza vaccine “mRNA-1010” (brand name: mFlusiva). The vote was 9 to 0. The decision came after a former Trump administration appointee initially refused to review the vaccine.

Review Background

The approval recommendation was made during a full-day meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). Committee members reviewed clinical trial data submitted by Moderna and a review report from FDA scientists. The FDA’s scientific team had given a favorable assessment of the vaccine.

Notably, an unusual situation occurred a few months earlier in February 2026. Vinay Prasad, then appointed by the Trump administration to head vaccine review at the FDA, decided to reject Moderna’s application, effectively refusing to even conduct the review. Prasad argued that “a comparative trial with a high-dose vaccine for adults aged 65 and older was insufficient,” but Moderna countered that it had followed a pre-agreed plan with the FDA to compare immune responses in a separate small-scale trial. Moderna was reported to have been caught off guard by the rejection.

Clinical Trial Results

The data evaluated by VRBPAC came from two Phase 3 trials. A large-scale trial involving more than 40,000 adults aged 50 and older showed that the mRNA vaccine was approximately 27% more effective against seasonal influenza compared to standard influenza vaccines. A smaller trial of about 3,000 adults aged 65 and older confirmed that the vaccine induced a stronger immune response than the high-dose influenza vaccine recommended for that age group. The safety profile was generally assessed as good.

Committee Assessments

VRBPAC voting member Flor Munoz-Rivas, a pediatric infectious disease specialist at Baylor College of Medicine, said after the vote: “The trials presented today were very well designed and yielded extremely robust results in demonstrating additional efficacy.” She further noted the agility of the mRNA platform, stating, “It enables rapid vaccine development in the context of regular seasonal influenza activity,” and called it “promising as a preparation for future emerging strains and pandemic strains.”

Stanford University pediatric infectious disease specialist Hayley Gans echoed this sentiment, saying: “This platform offers an exciting way to move vaccines into the future. The signals currently identified do not expose people to risk, and the benefit is great not just for this season but for the entire vaccine platform.”

Editorial Opinion

This approval recommendation demonstrates that mRNA technology is steadily expanding beyond COVID-19 vaccines into the seasonal vaccine arena. In the short term, if the FDA grants formal approval, Moderna will gain a new revenue stream, and the impact on competing conventional vaccine manufacturers cannot be ignored. The 27% improvement in efficacy could make a significant difference in clinical settings. In the long term, the mRNA platform may shift the paradigm of influenza prevention by enabling rapid vaccine updates based on annual strain predictions. However, the recent turmoil in which political intervention threatened to distort scientific evaluation raises fundamental questions about the independence of administrative agencies. The balance between regulatory processes and political appointments appears to be an issue directly tied to trust in the biotechnology industry.

References

• FDA advisors unanimously vote to approve Moderna’s mRNA after agency drama - Ars Technica — Published June 18, 2026